Pazopanib Clinical Trials

5 actively recruiting trials across 3 locations

▲ +1 trial since June 2026

Also known as: GW786034, VOTRIENT®, Votrient®

Pipeline

Phase 2: 2Phase 3: 1Phase 1/2: 1

Top Sponsors

Xynomic Pharmaceuticals, Inc.1
St. Jude Children's Research Hospital1
Shandong Cancer Hospital and Institute1
M.D. Anderson Cancer Center1
Imbioray (Hangzhou) Biomedicine Co., Ltd.1

Indications

Cancer5
Recurrent Sarcoma1
Rhabdomyosarcoma, Recurrent, Refractory1
Osteosarcoma, Extraskeletal1
Myxofibrosarcoma1

Other2 trials

A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma

Phase 2

Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents

Phase 2

Phoenix, Arizona1 trial

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

University Of UA Cancer Center(UACC)/DH-SJHMC

Phase 3

Atlanta, Georgia1 trial

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Children's Healthcare of Atlanta

Phase 1/2

Houston, Texas1 trial

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

M D Anderson Cancer Center

N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.